Trastuzumab

Herceptin (trastuzumab) for HER2-Positive Breast and Stomach Cancer

Oncology Associates

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?

INNOVATION: chemotherapy with trastuzumab and pertuzumab in HER2+ gastric cancer

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer

Dana-Farber Cancer Institute

Dr. Pegram on Pertuzumab and Trastuzumab in Breast Cancer

Targeted Oncology

PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer

Dr. Piccart on the Success of Trastuzumab

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer

GASTHER2: trastuzumab for advanced gastric cancer

APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancer

Dr. Mark Pegram on Combining Trastuzumab and Pertuzumab

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer

Dr. O’Regan on the Mechanism of Action of Trastuzumab

Targeted Oncology

Trastuzumab and cardiovascular disease risk – Video abstract [69641]

Dove Medical Press

Trastuzumab deruxtecan in metastatic HER2+ breast cancer

Dr. Jhaveri on the Use of Trastuzumab Biosimilars in Breast Cancer

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer